ESMO Congress 2024: A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib Poster:1309P - A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900AThis research is being presented at ESMO Congress 2024. View all presentation abstracts at esmo.org.For more information about Foundation Medicine at ESMO Congress 2024, visit the event page here. HRDsig Lung Cancer Comprehensive Genomic Profiling September 10, 2024